Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abingdon Health PLC ( (GB:ABDX) ) has shared an announcement.
Abingdon Health plc, a specialist in contract development and manufacturing of lateral flow diagnostics, supports clients from concept through regulatory approval and routine production from facilities in York and Doncaster in the UK and Madison, Wisconsin. Its subsidiaries also provide regulatory consulting and analytical testing to help in vitro diagnostic and medical device companies secure market access in major territories.
The company highlighted the UK commercial launch of LVOne, billed as the first rapid blood test to identify stroke at the point of care, developed by customer UpFront Diagnostics and now being deployed with the London Ambulance Service. Acting as CDMO partner, Abingdon handled feasibility, scale-up, validation and routine manufacture of LVOne’s dual-biomarker assays, with the initial rollout equipping around 280 ambulances in a six‑month London pilot, underscoring Abingdon’s role in translating complex lateral flow projects into market-ready products.
Spark’s Take on ABDX Stock
According to Spark, TipRanks’ AI Analyst, ABDX is a Neutral.
The score is held back primarily by weak financial quality—ongoing losses, declining gross margin, and negative operating cash flow—despite strong revenue growth. Technicals are supportive with the price above major moving averages and a positive MACD, but elevated RSI indicates potential near-term overheating. Valuation is constrained by negative earnings and the absence of a dividend yield.
To see Spark’s full report on ABDX stock, click here.
More about Abingdon Health PLC
Abingdon Health plc is a UK-headquartered med-tech contract service provider specialising in rapid diagnostic tests and regulatory services for an international customer base. The group’s CDMO operations develop and manufacture lateral flow assays across areas such as infectious disease, clinical testing, animal health and environmental testing, supported by in-house analytical and regulatory consulting capabilities in the UK and the U.S.
Average Trading Volume: 381,897
Technical Sentiment Signal: Buy
Current Market Cap: £30.13M
For an in-depth examination of ABDX stock, go to TipRanks’ Overview page.